Genmab chief on sclerosis drug launch: Novartis prioritizes us

While Genmab's partner Novartis can start launching sclerosis drug Kesimpta in Europe after receiving EU authorization, the process is well underway in the US – and it's going well, according to CEO Jan van de Winkel.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

WS Audiology plans to list subsidiary

Privately-owned hearing aid company WS Audiology, which grew out of the merger between Widex and Sivantos, plans to list, which handles online sales.

Further reading

Related articles

Latest news

See all jobs